Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW.

Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16069. [Epub ahead of print] No abstract available.

PMID:
31234236
2.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

PMID:
30514704
3.

"Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission.

Rady K, Blombery P, Westerman DA, Wall M, Curtis M, Campbell LJ, Seymour JF.

Leuk Res. 2018 Oct;73:1-4. doi: 10.1016/j.leukres.2018.08.010. Epub 2018 Aug 16.

PMID:
30170269
4.

Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay.

Blombery PA, Ryland GL, Markham J, Guinto J, Wall M, McBean M, Jones K, Thompson ER, Cameron DL, Papenfuss AT, Prince MH, Dickinson M, Westerman DA.

Br J Haematol. 2018 Oct;183(1):146-149. doi: 10.1111/bjh.14919. Epub 2017 Sep 7. No abstract available.

PMID:
28880377
5.

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.

Agarwal R, Blombery P, McBean M, Jones K, Fellowes A, Doig K, Forsyth C, Westerman DA.

Ann Hematol. 2017 May;96(5):725-732. doi: 10.1007/s00277-017-2937-6. Epub 2017 Feb 4.

PMID:
28161773
6.

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.

Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben J, Robinson MD, Purton LE, Bonnet D, Lo Celso C.

Nature. 2016 Oct 27;538(7626):518-522. doi: 10.1038/nature19801. Epub 2016 Oct 17.

7.

Risk of thromboembolism with lymphoma: myth or reality?

Burbury KL, Alexander M, Westerman DA.

Leuk Lymphoma. 2016 Dec;57(12):2736-2738. Epub 2016 Jul 5. No abstract available.

PMID:
27379822
8.

Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.

Agarwal R, Lade S, Liew D, Rogers TM, Byrne D, Feleppa F, Juneja S, Westerman DA.

J Clin Pathol. 2016 Mar;69(3):266-70. doi: 10.1136/jclinpath-2015-203002. Epub 2015 Aug 25.

PMID:
26307073
9.

Prevention of thromboembolism in myeloma: expanding the tool-box of assays to predict the risk?

Burbury KL, Dickinson M, Westerman DA, Prince HM.

Leuk Lymphoma. 2015;56(12):3246-7. doi: 10.3109/10428194.2015.1055487. Epub 2015 Jul 7. No abstract available.

PMID:
26054250
10.

Ependymal cells in cerebrospinal fluid: a traumatic occurrence.

Yeh P, Westerman DA.

Blood. 2015 Mar 19;125(12):2005. No abstract available.

11.

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.

Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM.

Blood. 2015 Jan 1;125(1):71-81. doi: 10.1182/blood-2014-07-588236. Epub 2014 Oct 21.

12.

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.

Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF.

Br J Cancer. 2014 Sep 9;111(6):1072-9. doi: 10.1038/bjc.2014.405. Epub 2014 Jul 29.

13.

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.

Herbert KE, Demosthenous L, Wiesner G, Link E, Westerman DA, Came N, Ritchie DS, Harrison S, Seymour JF, Prince HM.

Bone Marrow Transplant. 2014 Aug;49(8):1056-62. doi: 10.1038/bmt.2014.112. Epub 2014 Jun 2.

PMID:
24887382
14.

KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis.

Agarwal R, McBean M, Hewitt C, Westerman DA.

Leuk Lymphoma. 2014 Sep;55(9):2202-3. doi: 10.3109/10428194.2013.876498. Epub 2014 Jan 28. No abstract available.

PMID:
24359244
15.

Cerebrospinal fluid analysis by flow cytometry in acute lymphoblastic leukemia: is it all that it is cracked up to be?

Davis IR, Westerman DA.

Leuk Lymphoma. 2014 Jul;55(7):1441-3. doi: 10.3109/10428194.2013.876499. Epub 2014 Feb 24. No abstract available.

PMID:
24354685
16.

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM.

Mol Ther. 2013 Nov;21(11):2122-9. doi: 10.1038/mt.2013.154. Epub 2013 Jul 8.

17.

Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment.

Burbury KL, Westerman DA.

Leuk Lymphoma. 2014 Apr;55(4):749-60. doi: 10.3109/10428194.2013.820291. Epub 2013 Aug 20. Review.

PMID:
23808833
18.

A no-prophylaxis platelet-transfusion strategy for hematologic cancers.

Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, Norfolk D, Copplestone A, Smith N, Kerr P, Jones G, Raj K, Westerman DA, Szer J, Jackson N, Bardy PG, Plews D, Lyons S, Bielby L, Wood EM, Murphy MF; TOPPS Investigators.

N Engl J Med. 2013 May 9;368(19):1771-80. doi: 10.1056/NEJMoa1212772.

19.

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.

Zapparoli GV, Jorissen RN, Hewitt CA, McBean M, Westerman DA, Dobrovic A.

BMC Cancer. 2013 Apr 24;13:206. doi: 10.1186/1471-2407-13-206.

20.

Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques.

Blombery PA, Dickinson M, Westerman DA.

Leuk Lymphoma. 2014 Jan;55(1):19-30. doi: 10.3109/10428194.2013.792112. Epub 2013 May 9. Review.

PMID:
23550993
21.

Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?

Burbury KL, Seymour JF, Dauer R, Westerman DA.

Leuk Lymphoma. 2013 Jan;54(1):11-3. doi: 10.3109/10428194.2012.710908. Epub 2012 Sep 10. No abstract available.

PMID:
22906133
22.

Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders.

Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, Grigoriadis G, Westerman DA.

Haematologica. 2012 May;97(5):780-3. doi: 10.3324/haematol.2011.054874. Epub 2011 Dec 1.

23.

Short-term warfarin reversal for elective surgery--using low-dose intravenous vitamin K: safe, reliable and convenient*.

Burbury KL, Milner A, Snooks B, Jupe D, Westerman DA.

Br J Haematol. 2011 Sep;154(5):626-34. doi: 10.1111/j.1365-2141.2011.08787.x. Epub 2011 Jul 14.

PMID:
21751986
24.

Flow-cytometric minimal residual disease monitoring for chronic lymphocytic leukemia in the post-allogeneic transplant period.

Cargo CA, Westerman DA, Gambell P, Juneja S, Szer J, Ritchie D.

Leuk Lymphoma. 2011 Nov;52(11):2185-7. doi: 10.3109/10428194.2011.585530. Epub 2011 Jun 30. No abstract available.

PMID:
21718135
25.

Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications.

Blombery P, Prince HM, Worth LJ, Main J, Yang M, Wood EM, Westerman DA.

Ann Hematol. 2011 Oct;90(10):1167-72. doi: 10.1007/s00277-011-1275-3. Epub 2011 Jun 15.

PMID:
21674144
26.

Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.

Pasricha SR, Juneja SK, Westerman DA, Came NA.

J Clin Pathol. 2011 Jun;64(6):520-3. doi: 10.1136/jcp.2010.088591. Epub 2011 Apr 6.

PMID:
21471142
27.

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF.

Leukemia. 2010 Dec;24(12):2056-62. doi: 10.1038/leu.2010.218. Epub 2010 Oct 21.

PMID:
20962860
28.
29.

Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.

Tan AY, Westerman DA, Carney DA, Seymour JF, Juneja S, Dobrovic A.

J Hematol Oncol. 2008 Jul 29;1:10. doi: 10.1186/1756-8722-1-10.

30.

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.

Bishton MJ, Hicks RJ, Westerman DA, Prince MH, Wolf M, Seymour JF.

Haematologica. 2008 May;93(5):789-90. doi: 10.3324/haematol.12253. No abstract available.

31.

Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.

Ritchie DS, McBean M, Westerman DA, Kovalenko S, Seymour JF, Dobrovic A.

Blood. 2008 Mar 1;111(5):2896-8. Epub 2007 Dec 11.

32.

Quality of bone marrow iron assessment.

Came NA, Westerman DA.

Pathology. 2007 Dec;39(6):610; author reply 611. No abstract available.

PMID:
18027272
33.

A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.

Tan AY, Westerman DA, Dobrovic A.

Am J Clin Pathol. 2007 Jun;127(6):977-81.

PMID:
17509995
34.

Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases.

Ng AP, Lade S, Rutherford T, McCormack C, Prince HM, Westerman DA.

Haematologica. 2006 Jan;91(1):143-4.

35.

Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count.

Gibbs SD, Westerman DA, Lade S, McCormack C, Seymour JF, Prince HM.

J Am Acad Dermatol. 2005 Sep;53(3):535-6. No abstract available.

PMID:
16112376
36.
38.

Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome).

Morgan SJ, Prince HM, Westerman DA, McCormack C, Glaspole I.

Leuk Lymphoma. 2003 Sep;44(9):1623-5. Review.

PMID:
14565669
39.

Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab.

Herbert KE, Prince HM, Westerman DA.

Blood. 2003 Feb 15;101(4):1654. No abstract available.

40.

Test and teach. Number one hundred and one: Part 1.

Westerman DA, Juneja SK.

Pathology. 2000 May;32(2):118, 137-8. No abstract available.

PMID:
10840832
41.
42.

Neutrophil hypersegmentation in iron deficiency anaemia: a case-control study.

Westerman DA, Evans D, Metz J.

Br J Haematol. 1999 Dec;107(3):512-5.

PMID:
10583250
43.

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.

Talbot SM, Westerman DA, Grigg AP, Toner GC, Wolf M, Bishop J, McKendrick J, Zalcberg J, Levi J, Fox RM, Green MD.

Ann Oncol. 1999 Aug;10(8):907-14.

PMID:
10509151
44.
45.

Hydroxyurea-induced fever and hepatitis.

Westerman DA, Schwarer A, Grigg AP.

Aust N Z J Med. 1998 Oct;28(5):657-9. No abstract available.

PMID:
9847957
46.

Effects of topical capsaicin on normal skin and affected dermatomes in herpes zoster.

Westerman RA, Roberts RG, Kotzmann RR, Westerman DA, Delaney C, Widdop RE, Carter BE.

Clin Exp Neurol. 1988;25:71-84.

PMID:
3267488
47.

Factors influencing DRG 210 (hip fracture) reimbursement.

Agarwal N, Reyes JD, Westerman DA, Cayten CG.

J Trauma. 1986 May;26(5):426-31. Erratum in: J Trauma 1986 Nov;26(11):994.

PMID:
3084805

Supplemental Content

Loading ...
Support Center